CAPLIPOINT Caplin Point Laboratories Q1 FY26 results (Apr–Jun 2025) and concall
Caplin Point Laboratories reported a strong Q1 FY26 with 11.7% revenue growth and 20.1% PAT growth, driven by robust performance in the US (37% growth) and LATAM (7% growth). The company achieved its highest-ever contribution margin of 61.1% and maintained a zero-debt position. Strategic focus remains on expanding in larger Latin American markets, increasing value-added outsourcing from China, and cautious CAPEX deployment, though the OSD facility timeline was pushed back.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 483 | 493 | 502 | 510 |
| EBITDA | 165 | 162 | 168 | 178 |
| Net profit | 131 | 140 | 145 | 151 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
